Navigation Links
Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery

Chromatography and Mass Spectrometry Application Note

Key Words Sensitivity Quantitation Finnigan TSQ Quantum Discovery Enhanced Mass- Resolution

Xiaoying Xu1, Gary Paul2, Qiao Zhou1, Gregory Tucker1, and Walter Korfmacher1
1 Department of Drug Metabolism and Pharmacokinetics, Schering-Plough Research Institute, Kenilworth, NJ, USA; 2 Thermo Electron Corporation, Somerset, NJ, USA

Overview
Comparison of the limit of quantitation (LOQ) of a drug discovery compound in plasma at unit mass-resolution and enhanced mass-resolution on the Finnigan TSQ Quantum Discovery triple quadrupole mass spectrometer.

Introduction
Recent technological advances in atmospheric pressure ionization (API) techniques and instrumentation are revolutionizing the quantitation of pharmaceutical products.[1] The benchtop Finnigan TSQ Quantum Discovery provides a unique enhanced mass-resolution capability for a triple quadrupole mass spectrometer.[1-6] The utility of enhanced mass-resolution on the Q1 mass analyzer for parent ion selection in the selected reaction monitoring (SRM) experiment has been investigated in previous quantitation studies on the Finnigan TSQ Quantum Discovery. Improved analyte sensitivities were achieved at enhanced mass-resolution, relative to the typical unit mass-resolution mode of a triple quadrupole mass spectrometer.[2-6] These improvements were simply accomplished through the mass separation of the analyte of interest from isobaric matrix/chemical interferences, using the additional resolving power of the quadrupole mass analyzer.

In order to further investigate the benefits of enhanced mass-resolution on the Finnigan TSQ Quantum Discovery, the sensitivity of a drug discovery compound, present in a minimally-treated complex biological matrix, was compared at unit and enhanced mass-resolution. In this manner, an assessment of the improvement in LOQ for this compound at enhanced mass-resolution can be made.

Experimental

Chemicals and Reagents
Rat plasma was purchased from Bioreclamation Inc. (Hicksville,NY, USA). Optima-grade (99.9%) acetonitrile and methanol were obtained from Fisher Scientific Co. (Pittsburgh, PA,USA), ammonium acetate from Sigma Chemical Co.(St.Louis, MO,USA), and glacial acidic acid (99.99+%) from Aldrich Chemical Company (Milwaukee, WI,USA). Water was purified using a compact ultra-pure water system (EASYpure UV, Dubuque, IA,USA).

Sample Preparation
150 μL of internal standard (IS) in acetonitrile solution (conc. 10 ng/mL) was added to 50 μL of drug discovery compound A in rat plasma (concs. 250 ng/mL). After plasma precipitation, the mixture was vortexed for 30 s, and then centrifuged for 10 min. The supernatant was transferred to a clean 96-well plate for LC/MS/MS analysis.

HPLC
HPLC Column: Symmetry C18, 50 4.6 mm, 5 μm (Waters Corporation, Milford, MA,USA)
Mobile Phase A: 0.01 M ammonium acetate in MeOH/H2O (20:80, v/v)
Mobile Phase B: 0.01 M ammonium acetate in MeOH + 0.6 mL/L 10% acetic acid
Flow Rate: 0.8 mL/min Gradient: 5% B for 0.5 min, 5% B to 95%B for 0.5 min, 2.0 min hold at 95% B, return to 5% B at 3.0 min, 3.0 min run time
Divert to MS at 0.8 min Divert to waste at 2.0 min Injection Vol.: 8 μL
Column Temp.: Ambient Temperature
Autosampler Temp: 5C
Retention Time: Compound A - 1.2 min
Internal Standard - 1.5 min

Mass Spectrometer
Mass Spectrometer: Finnigan TSQ Quantum Discovery (ThermoElectron,San Jose,CA,USA)
Source: ESI Mode
Ion Polarity: Positive
Ion Transfer Tube Temperature: 350C
Spray Voltage: 3500 V
Sheath/Auxiliary Gas: Nitrogen
Sheath Gas: 80 arbitrary units
Auxiliary Gas: 20 arbitrary units
Collision Gas Pressure: 1.3 mTorr

The SRM conditions for compound A were as follows:
Parent m/z: 473.28
Product m/z: 456
Scan Width: 1 u
Scan Time: 0.2 s
Collision Energy: 20 eV
Q1 Peak Width (unit mass-resolution): 0.7 u FWHM
Q1 Peak Width (enhanced mass-resolution): 0.2 u FWHM
Q3 Peak Width: 0.7 u FWHM

The internal standard SRM conditions were as follows:
Parent m/z: 544.40
Product m/z: 306
Scan Width: 1 u
Scan Time: 0.2 s
Collision Energy: 28 eV
Q1 Peak Width (unit mass-resolution): 0.7 u FWHM
Q1 Peak Width (enhanced mass-resolution): 0.2 u FWHM
Q3 Peak Width: 0.7 u FWHM

Results and Discussion
The LC/ESI-SRM chromatograms for blank plasma spiked with the internal standard, collected on the Finnigan TSQ Quantum Discovery operating in unit mass-resolution mode (Q1, 0.7 u FWHM), are shown in Figure 1. The arrow shown in Figure 1 indicates the expected retention time of compound A (t = 1.2 min). It can be seen that significant background interference elutes at the same retention time as compound A in the blank plasma (Figure 1). However, when the same blank plasma sample was analyzed by the Finnigan TSQ Quantum Discovery operating at enhanced mass-resolution (Q1, 0.2 u FWHM), the background interference at t =1.2 min was greatly reduced, as shown in Figure 2. The reduction in background noise is a consequence of the added specificity afforded to the SRM experiment by the enhanced mass-resolution feature.

The LC/ESI-SRM chromatograms obtained at unit mass-resolution for compound A in plasma at a concentration of 250 ng/mL, are shown in Figure 3. Background interference to the signal of compound A at this concentration is clearly evident in the chromatographic trace. A calculated signal to noise (S/N) ratio of 8 is determined for this peak (Figure 3). Hence, the LOQ for compound A at unit mass-resolution can be assumed to be of the order of 250 ng/mL.

When the same sample of compound A (conc. 250 ng/mL) was analyzed at enhanced mass-resolution, a much cleaner SRM peak was observed, as shown in Figure 4. This is a consequence of the removal of a considerable amount of isobaric chemical interference from the analyte through the improved mass selectivity at enhanced mass-resolution. In addition to a more uniform SRM peak, an improved S/N ratio of 31 was obtained for compound A at enhanced mass-resolution, relative to unit mass-resolution (Figures 3,4). The dramatic decrease in background noise at the higher mass-resolution setting is responsible for the significant improvement in S/N ratio, despite the loss of a factor of 3-4 in peak height/area for compound A (Figures 3,4). An increase in analyte sensitivity at enhanced mass-resolution, relative to unit, has been reported in previous LC/ESI-SRM and LC/APCI-SRM quantitative studies on the Finnigan TSQ Quantum Discovery.[2-6] Indeed, one of the prior quantitative studies was based on the monitoring of SRM transitions involving small molecule losses,[6] analogous to the transition used in this work (m/z 473456, loss of 17 u). Since small molecule losses through collisionally-induced dissociation processes are common-place and the potential for matrix interference to the analyte SRM is much greater, analysis at enhanced mass-resolution should be an extremely viable method for improved quantitative performance in this situation.

Since the S/N ratio for compound A (conc. 250 ng/mL) at enhanced mass-resolution was above that required for the limit of quantitation (Figure 4), compound A was diluted by a factor of 10 (conc. 25 ng/mL) and reanalyzed. The LC/ESI-SRM chromatograms obtained using enhanced mass-resolution at the lower concentration of compound A are shown in Figure 5. A clearly-defined peak for compound A is observed which is easily quantifiable. Hence, using enhanced mass-resolution on the Finnigan TSQ Quantum Discovery, at least an order of magnitude decrease in LOQ for compound A is achieved, relative to unit mass-resolution operation, without the need for time-consuming chromatographic manipulations. Satisfactory precision and accuracy values for analytes present in plasma have been previously reported for quantitative studies on the Finnigan TSQ Quantum Discovery in enhanced mass-resolution mode.[3,4].

Previous quantitative studies using the Finnigan TSQ Quantum Discovery also found that improvement in analyte sensitivity obtained at enhanced mass-resolution, as shown here, is proportional to an increase in the linear dynamic range for the assay.[3,4,6] An extended linear dynamic range is advantageous in applications such as discovery pharmacokinetic (PK) studies to accommodate the variable concentrations of analytes in the study samples.[3]

References
1. Yang L, Amad M, Winnik WM, Schoen AE, Schweingruber H, Mylechreest I, Rudewiz PJ. Rapid Commun. Mass Spectrom. 2002; 16: 2060.
2. Jemal M, Ouyang, Z. Rapid Commun. Mass Spectrom. 2003; 17: 24.
3. Xu X, Veals J, Korfmacher W. Rapid Commun. Mass Spectrom. 2003; 17: 832.
4. Hughes N, Winnik W, Dunyach JJ, Amad M, Splendore M, Paul G. J. Mass Spectrom, in press.
5. Xu X, Tucker G, Zhou Q, Veals J, Korfmacher, W. 50th ASMS Conf Mass Spectrometry and Allied Topics, Orlando, FL, 2002.
6. Paul G, Winnik W, Schmidt C, Amad M, Splendore M, Lytle C, Hughes JE, Desai B, MacKenzie, KI. 50th ASMS Conf Mass Spectrometry and Allied Topics, Orlando, FL, 2002.


'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. Increased Sensitivity in Microarray Analysis
2. Increased Transfer Efficiency Using a Discontinuous Buffer System With the Trans-Blot SD Cell
3. Improved Sensitivity for Staining RNA with SYBR Gold Stain
4. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
5. Increase the Power and Sensitivity for Your cDNA Synthesis with the New Transcriptor Reverse Transcriptase
6. Femtogram Sensitivity of the Antipsychotic Drugs Raclopride and Ritanserin Using a Varian 1200L LC/MS/MS
7. Maintaining High Sensitivity when Working with Small-Volume Samples
8. High Sensitivity, Wide Dynamic Range, Horseradish Peroxidase (HRP) ELISA Using the LMax Microplate Luminometer (MaxLine Application Note #41)
9. Sensitivity and Quantitation using a Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer
10. Trace Analysis Optimizing Sensitivity Finnigan Surveyor PDA Detector
11. A Screen of shRNAs Targeting Tumor Suppressor Genes to Identify Factors Involved in Paclitaxel Sensitivity
Post Your Comments:
(Date:12/24/2014)... 23, 2014 Pipette.com announces their ... followers can submit their #HolidayInTheLab pictures for a chance ... mates. , For those struggling to think of a ... Holiday in the Lab Contest provides the ideal holiday ... to send pictures of their chemistree, holiday sweaters, ...
(Date:12/24/2014)... December 23, 2014 PharmaBoardroom,s ... out today and available for free download , digs ... change and growth in the sector today. One ... successes has been in developing a homegrown pharmaceutical manufacturing base, ... production still remains some way off. A cursory comparison with ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), a ... of autologous cell therapies, announced today the publication of ... conjunction with co-authors from Kyoto University and the University ... clinical research using dermal sheath cup (DSC) cells to ... paper entitled " Hair Follicle Dermal Stem Cells Regenerate ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5
... YM BioSciences Inc.,(AMEX: YMI , TSX: YM, ... commercializes differentiated products for patients worldwide,today announced that ... of its Phase II trial of nimotuzumab in ... The safety profile in the trial to,date is ...
... Lineup; Looks to Build Upon 2007 ... Record-Breaking Results, NEW YORK, Dec. 20 ... cure for breast cancer, the Avon,Foundation today announced the 2008 Avon Walk ... series will expand into a,ninth market -- Houston -- to build upon ...
... Calif., Dec. 20 Ardea Biosciences,Inc. (Nasdaq: ... and development of,small-molecule therapeutics for the treatment of ... it has entered into a,securities purchase agreement with ... the private placement of approximately 3.0,million newly issued ...
Cached Biology Technology:YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL 3Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 2Avon Foundation Announces 2008 Avon Walk for Breast Cancer Schedule 3Ardea Biosciences Announces $40 Million Private Placement 2Ardea Biosciences Announces $40 Million Private Placement 3
(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
(Date:11/21/2014)... MOUNTAIN VIEW, Calif. , Nov. 20, 2014 /PRNewswire/ ... for higher driver efficiency are piloting the North American ... the number of accidents growing, gesture recognition systems that ... will make a mark in the industry. ... of the Automotive Gesture Recognition Market in ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Inception Technologies to Release New Biometric Reader 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... new study provides support for Darwin,s hypothesis that ... closely related species than those distantly related. While ... contains the strongest direct experimental evidence yet to ... extinction occurred more frequently and more rapidly between ...
... that chytridiomycosis, a rapidly spreading amphibian disease, has reached ... last area in the entire mountainous neotropics to be ... the Panama Amphibian Rescue and Conservation Project, a consortium ... rescue 20 species of frogs in imminent danger of ...
... implementation of the Global Strategy for Plant Conservation," ... Conservation (GPPC) in association with the Secretariat of ... Gardens Conservation International (BGCI). The conference is expected ... share their experiences and further the development of ...
Cached Biology News:New study supports Darwin's hypothesis on competition between species 2New study supports Darwin's hypothesis on competition between species 3Scientists find deadly amphibian disease in the last disease-free region of central America 2Scientists find deadly amphibian disease in the last disease-free region of central America 3Global strategy for plant conservation conference to take place at the Missouri Botanical Garden 2Global strategy for plant conservation conference to take place at the Missouri Botanical Garden 3
... inhibitor) is a 50 kDa ... RNase activity. It does not ... , Inhibits RNase activity, ... , Lacks DNA endonuclease ...
UGT1A7 (E-15)...
Chicken Aortic Smooth Muscle Cells (CAOSMC) (>500,000 cells)...
... Start Taq Monoclonal Antibody ... the onset of thermal ... and primer-dimer formation. When ... the antibody is quickly ...
Biology Products: